Overview
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Eligibility
Inclusion criteria:
- Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
- Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
- Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
- Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
- Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
Exclusion criteria:
- Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid
- Pregnancy or breastfeeding
- Currently enrolled in an interventional study
- Currently enrolled in an observational study sponsored or managed by a Janssen company
